8-K: Evofem Biosciences Reports Strong Preliminary 2023 Results with Record Phexxi Sales and Reduced Operating Expenses

Evofem Biosciences announced strong preliminary 2023 results, including record net sales for Phexxi and a significant reduction in operating expenses.

Summary

• Evofem Biosciences reported preliminary net product sales between $18.1 and $18.3 million for 2023.
• This represents a significant increase compared to 2022, despite a 73% reduction in the field sales force and no growth capital investment.
• The company achieved a key milestone with net product sales exceeding sales and marketing expenses for 2023.
• Total operating expenses were reduced by more than 60% compared to 2022.
• The loss from operations improved by more than 75% compared to 2022.
• Evofem entered into a definitive agreement to be acquired by Aditxt, Inc. in December 2023, with the transaction expected to close in mid-2024.
• Full financial results for the threeand twelve-month periods ended December 31, 2023, are expected to be reported in mid-March 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to record sales, significant cost reductions, and a pending acquisition. However, the company is still not profitable and has a reduced sales force, which tempers the overall optimism.

Positives

• Phexxi net sales reached a record high in 2023, indicating strong product demand.
• The company demonstrated significant cost control by reducing operating expenses by over 60%.
• The improvement in loss from operations by more than 75% shows progress towards profitability.
• The acquisition by Aditxt is seen as a positive step to accelerate growth.
• Net product sales exceeded sales and marketing expenses for 2023, a key milestone.

Negatives

• The company had a 73% reduction in its field sales force in 2023.
• There was an absence of growth capital in 2023, which could have limited sales potential.
• The company is still operating at a loss, although the loss has been reduced.

Risks

• The company's future performance is subject to risks and uncertainties detailed in their SEC filings.
• The acquisition by Aditxt is subject to closing conditions and may not be completed.
• The company's ability to maintain sales growth with a reduced sales force is uncertain.

Future Outlook

Evofem expects to report full results for the threeand twelve-month periods ended December 31, 2023, in mid-March 2024 and anticipates the acquisition by Aditxt to close in mid-2024.

Management Comments

• Saundra Pelletier, CEO of Evofem Biosciences, stated that the company achieved its third consecutive year of revenue growth due to strong consumer demand for Phexxi and expansion of coverage and reimbursement.
• The CEO also highlighted that the company delivered more than $18 million in net sales for 2023 despite austerity measures and a reduced sales force.
• Management believes the acquisition by Aditxt is a compelling opportunity to accelerate growth.

Industry Context

The announcement reflects a positive trend for Evofem in the women's health market, particularly in the area of hormone-free contraception. The acquisition by Aditxt suggests a move towards consolidation and expansion in the sector.

Comparison to Industry Standards

• While specific competitor data is not provided, the 73% reduction in sales force while still achieving record sales is unusual and suggests a highly efficient sales process or a very strong product.
• The 60% reduction in operating expenses is significant and would be considered a very strong result compared to most companies in the sector.
• The improvement in loss from operations by more than 75% is a positive sign, but the company is still not profitable, which is not uncommon for companies in the growth phase.

Stakeholder Impact

• Shareholders may view the results and acquisition positively, potentially leading to an increase in share value.
• Employees may be impacted by the acquisition, with potential changes in roles and responsibilities.
• Customers are likely to benefit from the continued availability of Phexxi.
• Suppliers and creditors may see the acquisition as a positive sign of the company's stability.

Next Steps

• Evofem will report full financial results for the threeand twelve-month periods ended December 31, 2023, in mid-March 2024.
• The company is working towards closing the acquisition by Aditxt in mid-2024.

Key Dates

Keywords

Evofem Biosciences, Phexxi, Net Sales, Operating Expenses, Acquisition, Aditxt, Contraceptive, Women's Health, Financial Results